MINE (chemotherapy)

Medical treatment for lymphoma

MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.

Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.[citation needed]

The [R]-MINE regimen consists of:

1. Rituximab \- anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
2. Mesna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
3. Ifosfamide \- an alkylating antineoplastic agent from oxazafosforine group;
4. Mitoxantrone \- a synthetic anthracycline analogue (anthraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
5. Etoposide \- a topoisomerase inhibitor.[1][2]

## Dosing regimen

[edit]

Drug | Dose | Mode | Days

|
|
|

Rituximab | 375 mg/m2 | IV infusion | Day 1
Mesna | 1330 mg/m2 | IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide | Days 1-3
Ifosfamide | 1330 mg/m2 | IV infusion over 1h | Days 1-3
Mitoxantrone | 8 mg/m2 | IV infusion | Day 1
Etoposide | 65 mg/m2 | IV infusion over 1h | Days 1-3

## References

[edit]

1. ^ A phase II trial of mesna / ifosfamide, mitoxantrone and etoposide for refractory lymphomas
2. ^ Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.